Spero therapeutics added to the nasdaq biotechnology index

Cambridge, mass., dec. 16, 2020 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the nasdaq biotechnology index (nasdaq: nbi), effective prior to market open on monday, december 21, 2020.
SPRO Ratings Summary
SPRO Quant Ranking